Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
about
Crystal Structure of MraY, an Essential Membrane Enzyme for Bacterial Cell Wall SynthesisStructural insights into inhibition of lipid I production in bacterial cell wall synthesis.Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy.The cell envelope glycoconjugates of Mycobacterium tuberculosisAre natural products still the best source for antibacterial discovery? The bacterial entry factor.Biosynthesis of a water-soluble lipid I analogue and a convenient assay for translocase I.Discovery of a capuramycin analog that kills nonreplicating Mycobacterium tuberculosis and its synergistic effects with translocase I inhibitorsA reliable Pd-mediated hydrogenolytic deprotection of BOM group of uridine ureido nitrogenFluorescence-based assay for polyprenyl phosphate-GlcNAc-1-phosphate transferase (WecA) and identification of novel antimycobacterial WecA inhibitors.In vitro antimycobacterial activities of capuramycin analogues.Lipid Requirements for the Enzymatic Activity of MraY Translocases and in Vitro Reconstitution of the Lipid II Synthesis PathwayNatural product growth inhibitors of Mycobacterium tuberculosis.A biocatalytic approach to capuramycin analogues by exploiting a substrate permissive N-transacylase CapW.Activity of SQ641, a capuramycin analog, in a murine model of tuberculosisProgress in targeting cell envelope biogenesis in Mycobacterium tuberculosis.Therapeutic efficacy of SQ641-NE against Mycobacterium tuberculosis.Improved synthesis of capuramycin and its analogues.Antimicrobial nucleoside antibiotics targeting cell wall assembly: recent advances in structure-function studies and nucleoside biosynthesis.Antimycobacterial drugs currently in Phase II clinical trials and preclinical phase for tuberculosis treatment.Update on carbohydrate-containing antibacterial agents.The anti-tuberculosis agents under development and the challenges ahead.Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target.Concise synthesis of capuramycin.Chemical modification of capuramycins to enhance antibacterial activityN-Acetylglucosamine-1-phosphate transferase, WecA, as a validated drug target in Mycobacterium tuberculosis.Functional and kinetic analysis of the phosphotransferase CapP conferring selective self-resistance to capuramycin antibiotics.Development of new antituberculous agents based on new drug targets and structure-activity relationship.Permeability enhancing lipid-based co-solvent and SEDDS formulations of SQ641, an antimycobacterial agent.In vitro antimicrobial activities of capuramycin analogues against non-tuberculous mycobacteriaNew antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.Isolation and characterization of racemase from Ensifer sp. 23-3 that acts on α-aminolactams and α-amino acid amides.
P2860
Q27679836-CC7C5164-CEF4-4E82-BDE9-4DA81EE495CFQ28833309-87000319-CFDA-475C-9467-B0CD312CCB43Q34213604-DF1437B0-AFF2-4BAB-B76F-92496431A2C3Q34423962-DFA53591-30A8-4B73-87C9-14B3210E3AA3Q34619268-19904254-0013-4B58-BE61-F2A54C1BD16BQ34976154-E792C437-66BD-49EA-A918-EFB7EFAB767CQ35243846-57417C09-7C55-4AD0-9794-06C0C48AFCDEQ36033749-AFF18FAC-75E0-4233-B502-17B9E024425DQ36105224-718391AD-7243-485B-A97E-B8498DF212B5Q36424956-AE76868C-608C-48FB-8A3E-620A692B28D3Q36518393-32E8BD3C-D09B-4CCA-B392-ECD195813DE1Q36772385-61469D8A-DEED-47BC-94BE-BFD7287902BCQ36894291-C8E7F2D9-1BE5-45BF-A6B8-50C935C86A8CQ37247725-B27BE3C3-5E8C-40C9-B266-FCBDC1DE80EBQ37403156-86F78D55-8D84-475A-B3E9-E1C483DD8298Q37544338-BDB53786-7C56-4736-B986-41CC54A4CCD2Q37594561-CC6A6E4E-F01A-43FB-9A0E-A6C5484E17BDQ37683527-5834C0DC-F7C7-41E3-A4CF-C66CA25B0F94Q38044744-EBB374EC-420B-43C3-9DA1-E99102C0E7F2Q38089193-2AF68EE6-B61B-4941-B2FD-643B4773AC3AQ38617197-F27C397D-44C3-496B-9AF7-6461E2953A8EQ38782638-46D7ECC2-E555-4CFE-8A86-42424B8890F5Q38872743-6DC39833-4B66-4697-A3ED-3D3FD7189A63Q39615555-F3FD38CB-7D7A-407D-85B7-C242FB99D6B2Q40065984-38EAA0D6-1CD7-477C-81AD-59AC28394463Q40105078-7717F6CE-6751-4481-AF83-73381FBAD3CCQ40138610-B06F852C-FA39-48F6-BB89-E3131E258C16Q42209752-0A84D31B-DBA5-48A2-97C5-1C28C59B3CE7Q42374803-4F5D5016-FF4C-463D-8866-F4BC4CDF52B6Q47594312-8C9287E1-1A1F-4C15-AD3C-0566386FD13BQ47656133-4B228D0A-9936-4B5F-97A5-2F6849DB740B
P2860
Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Activity of capuramycin analog ...... ellulare in vitro and in vivo.
@en
Activity of capuramycin analog ...... ellulare in vitro and in vivo.
@nl
type
label
Activity of capuramycin analog ...... ellulare in vitro and in vivo.
@en
Activity of capuramycin analog ...... ellulare in vitro and in vivo.
@nl
prefLabel
Activity of capuramycin analog ...... ellulare in vitro and in vivo.
@en
Activity of capuramycin analog ...... ellulare in vitro and in vivo.
@nl
P2093
P356
P1476
Activity of capuramycin analog ...... ellulare in vitro and in vivo.
@en
P2093
Harumi Inoue
Hitoshi Hotoda
Masayo Kakuta
Misa Hoshi
Naotoshi Yamamura
Takashi Fukuoka
Takashi Hirota
Tamako Harasaki
Tetsufumi Koga
P304
P356
10.1093/JAC/DKH417
P407
P577
2004-09-03T00:00:00Z